Falk Gastro Info 10/2017

Video

Examination of the liver: Flow pattern of the portal vein, intercostal approach

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.
© 2017 Falk Foundation e.V., Freiburg. All rights reserved.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:

Bowel

Text:

Lawrance IC et al, Clin Gastroenterol Hepatol. 2017;15(8):1248–55

Therapy of ulcerative proctitis: Topical tacrolimus is highly efficient to induce clinical response, remission and mucosal healing in patients with resistant ulcerative proctitis.

Link to text

Text:

Schmidt A et al, Gut. 2017 [Epub ahead of print]

Endoscopic full-thickness resection (EFTR): EFTR has a reasonable technical efficacy especially in lesions ≤ 2 cm with acceptable complication rates. However, curative resection rate for early cancers was too low to recommend its primary use in this indication.

Link to text

Text:

de Jong MJ et al, Lancet. 2017;390(10098):959–68

Telemedicine for management of inflammatory bowel disease: Telemedicine is safe and reduces outpatient visits and hospitalizations compared to standard care without negatively affecting patients-reported quality of care.

Link to text

Liver Biliary Tracts

Text:

Kim JH et al, Hepatology. 2017;66(2):335–43

Hepatitis B: Low level viremia (HBV DNA-positive, but < 2000 IU/ml) during entecavir therapy is associated with an increased risk of hepatocellular carcinoma, especially in patients with cirrhosis. Thus, patients with cirrhosis and positive HBV DNA during potent antiviral therapy should be considered for treatment modification. [x_button type="transparent" shape="pill" size="regular" block="false" circle="false" icon_only="false" href=" http://www.drfalkpharma.com/index.php?L=1&id=24614#c34109" title="" target="blank" info="none" info_place="top" info_trigger="hover" info_content=""]Link to text[/x_button] Text: Poordad F et al, Hepatology. 2017;66(2):389–97

Hepatitis C: In patients with hepatitis C virus genotype 1 infection and prior failure of direct-acting antivirals, treatment with glecaprevir plus pibrentasvir is highly efficacious (sustained virological response > 90%). Addition of ribavirin does not improve efficacy.

Link to text

Text:

Fickert P et al, J Hepatol. 2017;67(3):549–58

Primary sclerosing cholangitis (PSC): norUrsodeoxycholic acid reduces serum levels of alkaline phosphatase significantly and in a dose-dependent manner. The safety profile of norUDCA is favorable. Based on these positive results, a phase III trial of norUDCA in PSC patients is performed.

Link to text

Oesophagus Stomach Duodenum

Text:

Wolf J et al, Gastroenterology. 2017;153(2):410–9.e17

Diagnosis of celiac disease (CD): This prospective study confirms that CD can be safely diagnosed based on serology (combination of total IgA and anti-transglutaminase IgA or anti-transglutaminase IgA and anti-gliadin IgG) without need for duodenal biopsy.

Link to text

Text:

Wang YF et al, Am J Gastroenterol. 2017;112(7):1084–93

Adverse events following proton pump inhibitor (PPI) therapy: This nationwide population-based study suggests that PPI use correlates with increased risk of first-time ischemic stroke in the general population.

Link to text

Text:

Cotton CC et al, Gastroenterology. 2017;153(3):681–8.e2

Barrett’s esophagus (BE): Although recurrence of BE or dysplasia occurs in one third of patients with dysplastic BE undergoing radiofrequency ablation, most patients relapse within the first year after complete eradication of intestinal metaplasia and late recurrences are rare.

Link to text

Pancreas

Text:

Crippa S et al, Am J Gastroenterol. 2017;112(7):1153–61

Follow-up for presumed branch-duct IPMNs Active surveillance beyond 5 years is recommended, since 1 out of 6 patients develops worrisome features or high-risk stigmata, suggesting that an intensification of follow-up should be considered after 5 years.

Link to text

International Symposia and Workshops

Symposium 208

IX GASTRO-CONFERENCE (Part I)
Eosinophilic Esophagitis – Medical and Dietary Treatment

October 4 – 5, 2017, Berlin, Germany
Maritim Hotel Berlin, Stauffenbergstr. 26, 10785 Berlin, Germany

Program

Registration

Online registration

Symposium 209

IX GASTRO-CONFERENCE (Part II)
IBD 2017 – Therapeutic and Biological Barriers

October 6 – 7, 2017, Berlin, Germany
Maritim Hotel Berlin, Stauffenbergstr. 26, 10785 Berlin, Germany

Program